COMMUNIQUÉS West-GlobeNewswire

Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
21/04/2026
Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage [...]
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform
21/04/2026
Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug conjugate (ADC) [...]
Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For”
21/04/2026
Santa Rosa Nonprofit Earns National Recognition for Exceptional Workplace Culture and Employee Experience SANTA ROSA, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Becoming Independent , a nonprofit supporting adults with [...]
AuX Labs Secures $4M to Commercialize Precision Fermentation Cheese Platform
21/04/2026
Funding will accelerate the launch of a scalable, precision-fermented dairy protein technology that performs like traditional cheese TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- AuX Labs, a food technology company using [...]
Eclipse Energy and Wood to Scale Hydrogen Production from End-of-Life Oil Fields
21/04/2026
Strategic collaboration positions Wood as a preferred engineering partner as Eclipse moves its reservoir-to-hydrogen technology toward global project development HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- As demand [...]
Celularity Announces Closing of Transaction with NexGel
21/04/2026
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously [...]
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
21/04/2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical [...]
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
21/04/2026
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
21/04/2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
21/04/2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
21/04/2026
Formal decision expected in May 2026 ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for [...]
Twentyeight Health Launches First Nationwide All-in-One Virtual Clinic & Personalized Care for Women
21/04/2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Twentyeight Health, the leading provider-led digital-first women’s healthcare platform today announces the launch of Complete Care, an insurance-enabled membership model [...]
QHSLab (OTCQB:USAQ) Reports 127% Year-Over-Year ISP Growth and Launches Q-Connect GLP-1 Support Assessment
21/04/2026
Unaudited Q1 2026 ISP revenue of $370,000, up from $163,000 in Q1 2025, representing 127% year-over-year growth Growth supported by expanding provider adoption, the launch of the Q-Connect AOM and GLP-1 Support [...]
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
21/04/2026
Expansion Adds to Growing Global Trial Footprint Patient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), [...]
Brain Cancer Canada Marks Brain Cancer Awareness Month in May with National Landmark Lightings, Community Events, New Research Investments, and a Call to Action
21/04/2026
Awareness events Research grant awards Gala for Brain Cancer Research with Catherine Wreford and Dr. Cynthia Hawkins TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the only national charity [...]
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
21/04/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established [...]
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
21/04/2026
DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial [...]
New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics
21/04/2026
Research published in the Journal of Clinical Microbiology PORTOLA VALLEY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a national nonprofit and leading sponsor of tick-borne disease research in [...]
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
21/04/2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]

Pages